Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19020085 | INHIBITORS OF KIF18A AND USES THEREOF | January 2025 | June 2025 | Allow | 5 | 0 | 1 | No | No |
| 18977370 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18823214 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | September 2024 | March 2025 | Allow | 6 | 0 | 1 | No | No |
| 18655062 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | May 2024 | March 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18651214 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | April 2024 | March 2025 | Allow | 11 | 1 | 1 | No | No |
| 18702485 | 5 ALPHA DIHYDROTESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS OF USE AND TREATMENT | April 2024 | March 2025 | Allow | 11 | 3 | 0 | Yes | No |
| 18589461 | PRMT5 INHIBITING COMPOUNDS AND USES THEREOF | February 2024 | March 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18433879 | NOVEL DRP-1 INHIBITORS AS THERAPEUTIC AGENTS | February 2024 | October 2024 | Allow | 9 | 1 | 1 | No | No |
| 18412741 | SELECTIVE HYPOXIA INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITORS | January 2024 | June 2024 | Allow | 5 | 0 | 0 | No | No |
| 18522287 | NOVEL CRYSTAL FORM F OF TRELAGLIPTIN AND PREPARATION METHOD THEREOF | November 2023 | February 2025 | Allow | 15 | 0 | 0 | No | No |
| 18209119 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | June 2023 | April 2025 | Allow | 22 | 0 | 1 | No | No |
| 18164346 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | February 2023 | May 2025 | Allow | 27 | 0 | 1 | No | No |
| 18160082 | PARP7 INHIBITORS | January 2023 | December 2024 | Allow | 22 | 1 | 1 | No | No |
| 17981306 | Canker sore preparation for the treatment of canker sore. | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17932386 | DIPHENYL THIOUREA AND DIPHENYL UREA DERIVATIVES AS INHIBITORS OF ENDOCYTOSIS | September 2022 | June 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17874838 | Composition Of Ferric Maltol For Oral Administration | July 2022 | April 2025 | Allow | 33 | 3 | 0 | No | No |
| 17866382 | PREVENTION OF THE CONVERSION OF PHARMACEUTICAL AGENTS INTO TOXIC N-NITROSAMINE COMPOUNDS | July 2022 | December 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17787207 | PROCESS FOR THE PREPARATION OF A CHIRAL PROSTAGLANDIN ENOL INTERMEDIATE AND INTERMEDIATE COMPOUNDS USEFUL IN THE PROCESS | June 2022 | September 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17548269 | MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE | December 2021 | February 2024 | Abandon | 26 | 1 | 1 | Yes | No |
| 17540269 | ANTIMICROBIAL COMPOSITION COMPRISING MALEIC ACID/VINYL ETHER COPOLYMER | December 2021 | November 2024 | Abandon | 36 | 2 | 1 | Yes | No |
| 17598187 | A SALT AND CRYSTAL FORM OF A FAK INHIBITOR | September 2021 | June 2025 | Allow | 45 | 1 | 0 | No | No |
| 17435863 | Orai Channel Inhibitors | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17431007 | 6-OXO-1,6-DIHYDROPYRIDAZINE PRODRUG DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | August 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17428997 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17428850 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | August 2021 | January 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17428556 | Sclerostin Inhibitors That Promote Bone Morphogenetic Protein Expression | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17422108 | DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY | July 2021 | July 2024 | Allow | 36 | 0 | 0 | No | No |
| 17421867 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17415236 | TREATMENT OF MOVEMENT DISORDERS | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17296693 | Cosmetic Mask Comprising a Plant Paper and Humectant | May 2021 | June 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17326383 | CONTINUOUS PROCESS FOR MANUFACTURING ALKYL 7-AMINO-5-METHYL-[1,2,5]OXADIAZOLO[3,4-B]PYRIDINE-CARBOXYLATE | May 2021 | March 2024 | Allow | 33 | 1 | 0 | No | No |
| 17293155 | METHODS OF TREATING CANCER | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17293114 | PHARMACEUTICAL COMPOSITION FOR TREATING DIFFUSE-TYPE GASTRIC CANCER | May 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17293292 | MACROCYCLIC INHIBITORS OF DYRK1A | May 2021 | July 2024 | Allow | 38 | 0 | 1 | No | No |
| 17290727 | PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS | April 2021 | April 2024 | Allow | 36 | 1 | 0 | No | No |
| 17283948 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17283111 | TOPICAL COMPOSITIONS | April 2021 | December 2024 | Abandon | 44 | 1 | 1 | Yes | No |
| 17280319 | COMPOUNDS THAT ENHANCE THE ACTION OF METFORMIN | March 2021 | March 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17280049 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17173669 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | February 2021 | May 2025 | Abandon | 51 | 4 | 0 | No | No |
| 17264478 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | January 2021 | December 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 17264638 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | January 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17264411 | DIFFUSION ENHANCING COMPOUNDS AND THEIR USE WITH THROMBECTOMY AND EMBOLECTOMY AND OTHER VASCULAR DISEASE PROCEDURES | January 2021 | April 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17155865 | TAAR Receptor Agonists for the Treatment of Alopecia | January 2021 | April 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17262682 | COMPOUNDS, DERIVATIVES, AND ANALOGS FOR CANCER | January 2021 | December 2023 | Allow | 34 | 0 | 0 | No | No |
| 17262082 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | January 2021 | June 2025 | Allow | 53 | 2 | 1 | No | No |
| 17261129 | CHALCONES AND DERIVATIVES FOR USE IN MEDICAMENTS AND NUTRACEUTICALS | January 2021 | March 2024 | Abandon | 38 | 1 | 0 | No | No |
| 15733874 | Mitochondrial Conductance Inhibitors and Methods of Use Thereof | November 2020 | August 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17055425 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | November 2020 | April 2025 | Allow | 53 | 2 | 1 | No | No |
| 16980003 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | September 2020 | January 2025 | Abandon | 52 | 2 | 1 | No | No |
| 16977485 | PROCESS AND INTERMIDIATES FOR THE PREPARATION OF CERTAIN MESOIONIC PESTICIDES | September 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner RAMOS LEWIS, JOSMALEN MILAGROS works in Art Unit 1621 and has examined 42 patent applications in our dataset. With an allowance rate of 42.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner RAMOS LEWIS, JOSMALEN MILAGROS's allowance rate of 42.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAMOS LEWIS, JOSMALEN MILAGROS receive 1.07 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RAMOS LEWIS, JOSMALEN MILAGROS is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +17.1% benefit to allowance rate for applications examined by RAMOS LEWIS, JOSMALEN MILAGROS. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 38.9% of applications are subsequently allowed. This success rate is in the 87% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 25.0% are granted (fully or in part). This grant rate is in the 15% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.1% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.